Teva Study Examines Treatment Selection in Schizophrenia

Tel Aviv, Israel, September 18, 2026

Teva Study Examines Key Treatment Attributes

The study was designed to better understand the relative importance of treatment attributes that influence healthcare providers when choosing an antipsychotic therapy. Teva researchers evaluated preferences among healthcare professionals involved in the management of schizophrenia, examining how different characteristics can affect treatment selection in routine clinical practice. Treatment decisions in schizophrenia can involve multiple considerations beyond symptom control. Healthcare providers may consider a medicine’s clinical effectiveness, safety profile, administration schedule, adherence potential and practical requirements when determining an appropriate treatment approach. The new Teva research provides a structured assessment of these factors and their relative importance to healthcare providers.

According to the study findings, treatment effectiveness and safety were among the important considerations for healthcare providers when evaluating treatment options. Other characteristics, including dosing frequency and treatment continuity, also contributed to treatment preferences. These findings highlight the multifaceted nature of treatment selection in schizophrenia, where clinical and practical considerations can intersect. The research adds to the growing body of evidence examining how healthcare professionals make treatment decisions in real-world settings. Understanding these preferences can provide pharmaceutical developers and healthcare organizations with additional information about factors that may influence treatment adoption and continued use.

Long-Acting Injectable Treatments in Focus

The study is particularly relevant to the increasing use of long-acting injectable (LAI) antipsychotics in schizophrenia management. LAI therapies can provide an alternative to daily oral medication by delivering medicine at longer intervals, potentially addressing challenges associated with daily medication administration. Healthcare providers evaluating LAI treatments may consider factors such as injection frequency, treatment adherence, patient preferences, tolerability and clinical effectiveness. The Teva study provides additional information about how these characteristics are weighed during treatment selection.

Treatment adherence remains an important consideration in schizophrenia because inconsistent medication use can contribute to symptom recurrence and other negative clinical outcomes. LAI formulations are designed to reduce the need for daily medication administration, although individual treatment decisions depend on the patient’s clinical circumstances, preferences and healthcare-provider assessment. The findings also demonstrate the importance of understanding treatment attributes from the perspective of healthcare professionals. While clinical trial data provide evidence about a medicine’s efficacy and safety, provider-preference research can offer complementary information about how therapies may be evaluated in everyday clinical practice.

Teva Expands Evidence in Schizophrenia Care

For Teva Pharmaceuticals, the study adds to the company’s broader research program in schizophrenia and long-acting injectable treatments. The company has developed and commercialized several medicines for central nervous system disorders and continues to investigate approaches that may support long-term treatment of serious psychiatric conditions. The findings were presented alongside other Teva research at Psych Congress 2026, where the company highlighted clinical and real-world evidence involving antipsychotic treatments. The broader research program includes studies examining treatment continuity, healthcare utilization and patient outcomes associated with long-acting injectable therapies. The new provider-preference findings are relevant because healthcare professionals play a central role in determining which treatment is appropriate for individual patients. A clearer understanding of the characteristics clinicians prioritize may help inform future research, treatment development and discussions between healthcare providers and patients.

However, provider preference studies do not establish that one treatment is clinically superior to another. Instead, they provide information about treatment-selection priorities and the factors that may influence prescribing decisions. These findings should therefore be considered alongside clinical efficacy, safety, patient characteristics and individual treatment needs. As schizophrenia treatment continues to evolve, research into clinical outcomes, treatment adherence, dosing strategies and healthcare-provider preferences remains an important part of pharmaceutical development. Teva’s latest study contributes to this research by examining how healthcare professionals assess treatment attributes when selecting therapies for adults with schizophrenia. The findings presented at Psych Congress 2026 reinforce the importance of considering both clinical and practical treatment characteristics in schizophrenia care. For pharmaceutical researchers and healthcare professionals, understanding these priorities can provide additional context for evaluating treatment options and designing future approaches to long-term disease management.

Source: Teva Pharmaceuticals press release